Full Text
What Impact Does Nice’s Modified Cancer Drugs Fund Process Mean For Patient Access To New Oncology Pharmaceuticals In England?

Abstract

Authors

P Craddy E Butler S Bailey V Wolfram G Foxon

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×